Aimmune Therapeutics (AIMT): Early Enrollment Completion Is A "Big Positive" - Piper Jaffray

September 21, 2016 9:42 AM EDT
Get Alerts AIMT Hot Sheet
Price: $15.00 +6.08%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 9 | New: 77
Trade AIMT Now!
Join SI Premium – FREE

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of Aimmune Therapeutics (NASDAQ: AIMT) after the company announced it has exceeded the North American enrollment of 350 patients in its Phase III PALISADE trial of AR101. This progress is a "big positive" driven by investigator and patient interest in the OIT mechanism, which is well-validated by Phase II efficacy & safety results, as well as non-sponsored trials. The analyst believes this projected timeline beat speaks to the unmet need in peanut allergy across the differentiated, broad patient population (range of ages and severities).

PALISADE, EU enrollment completion remains on track for 4Q16, setting up for top-line results in 4Q17. Additionally, in 1Q17, Aimmune will begin the 400-patient, placebo-controlled "real world" RAMSES trial, which will expand the growing body of efficacy, safety, and biomarker data on AR101.

No change to the price target of $38.00.

For an analyst ratings summary and ratings history on Aimmune Therapeutics click here. For more ratings news on Aimmune Therapeutics click here.

Shares of Aimmune Therapeutics closed at $15.81 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Related Entities

Piper Jaffray, Charles Duncan

Add Your Comment